Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2022-04-01
2025-03-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The specific aims of this study are to: (1) examine the efficacy of GC-MRT in PTSD; and (2) elucidate its underpinnings (i.e. attention control, reward processes, and exposure via counter-conditioning).
The investigators hypothesize that:
1. GC-MRT will produce greater reductions in symptoms compared to PC at post-treatment and follow-up (diverting attention away from threat).
2. GC-MRT-exp will produce greater reductions in symptoms compared to PC at post-treatment follow-up (exposure via counter-conditioning by rewarding threat stimuli).
3. Exploratory analysis will compare the reductions in symptoms of GC-MRT compared to GC-MRT-exp at post-treatment follow-up.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Testing the Efficacy of an Eye-tracking-based Treatment in Reducing Stress-related Symptoms in Veterans With PTSD
NCT05243459
Music-instruction Intervention for Treatment of Post-traumatic Stress Disorder
NCT03759171
Benefits of Relaxation by Music Therapy on PTSD Symptoms
NCT03990064
Neurofeedback of Amygdala Activity for Post-traumatic Stress Disorder
NCT03574974
Trial to Evaluate Efficacy of Magnetic Resonant Therapy (MRT) in PTSD
NCT02268084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The goal of this study is to: (1) examine the efficacy of GC-MRT in PTSD; and (2) elucidate its underpinnings (i.e. attention control, reward processes, and exposure via counter-conditioning).
Attention control is the ability to shift attention deliberately based on goal-directed behavior. Accordingly, deficits in attention control can result in volatile shifts in attention leading to increase attention allocation to threat in the environment.
Reward functioning is the ability to seek out and enjoy stimuli of positive motivational valence, and is considered a crucial driving force of behavior, guiding the organism towards positive and rewarding experiences, ranging from food and gender to money, music, and positive social interactions.
Allocating visual attention to rewarding stimuli is considered a reward-related attentional feature.
Counter-conditioning is an alternative to exposure therapy involving pairing of the feared stimulus with an appetitive/positive outcome (i.e., increasing the rewarding/positive value of the feared stimulus), in which repeated trials are supposed to reduce the fear response, and replace it by an appetitive response. Indeed, studies have shown counter-conditioning to be more effective at reducing fear than traditional exposure therapy.
The investigators hypothesize that:
1. GC-MRT will produce greater reductions in symptoms compared to PC at post-treatment and follow-up (diverting attention away from threat).
2. GC-MRT-exp will produce greater reductions in symptoms compared to PC at post-treatment follow-up (exposure via counter-conditioning by rewarding threat stimuli).
3. Exploratory analysis will compare the reductions in symptoms of GC-MRT compared to GC-MRT-exp at post-treatment follow-up.
Subject population: Seventy-five subjects with PTSD will participate in this study.
Methods: The sample (N = 75) will be randomized equally into three groups. Group 1 will receive a 4-week (8 sessions) course of GC-MRT where music will play only when viewing neutral faces, Group 2 will receive a 4-week (8 sessions) course of GC-MRT-exp where music will play only when viewing angry faces, and Group 3 will receive a 4-week (8-sessions) course of non-GC-MRT (i.e. placebo control; PC) where music will play throughout the trials.
\*The pictures of the faces used in the intervention will include 50% male and 50% female. Race-wise they are homogenous. Varying the different faces by race is not feasible as these faces were chosen from an established picture data-base (i.e., the Karolinska Directed Emotional Faces database; KDEF) based on the affective ratings of each face. Importantly, this composition of faces is similar to one used in an attention assessment task for which our pilot data shows significant group differences in dwell time, which is the attentional target of the intervention. Hence, we do not expect this to affect the results.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non-GC-MRT
Placebo- music will play at all times during the trials.
Placebo GC-MRT
Participants will hear music continuously throughout the trials, without regard to the faces they look at.
GC-MRT
Music will only play when participants view angry faces and will stop when they look at neutral faces.
GC-MRT
Participants will hear music as a reward for looking at neutral faces and the music will stop when they focus on angry faces.
GC-MRT-exp
Music will only play when participants look at neutral faces and will stop when they view angry faces.
Exposure
Participants will hear music of their choice when they focus on angry faces, and when they look at neutral faces the music will stop.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo GC-MRT
Participants will hear music continuously throughout the trials, without regard to the faces they look at.
GC-MRT
Participants will hear music as a reward for looking at neutral faces and the music will stop when they focus on angry faces.
Exposure
Participants will hear music of their choice when they focus on angry faces, and when they look at neutral faces the music will stop.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current DSM-5 diagnosis of PTSD
* CAPS-V score greater than or equal to 25
* Fluent in English and willing to give informed written consent and participate responsibly in the protocol.
* Normal or corrected-to-normal vision
* Mini Mental Status Exam score greater than or equal to 24.
Exclusion Criteria
* Current severe depression determined by a a) score greater than 25 on the Hamilton Rating Scale for Depression (HAM-D-17) and evaluation and b)clinical assessment
* Suicidal ideation or behavior
* Current or past diagnosis of obsessive compulsive disorder, bipolar disorder, epilepsy, or brain injury as determined by a Structured Clinical Interview for DSM-5 (SCID-5) interview
* Current or past organic mental disorder, seizure disorder, epilepsy or brain injury as determined by a clinical evaluation
* Diagnosis of probable Alzheimer's disease, Vascular Dementia, or Parkinson's Disease, as determined by a clinical evaluation and Mini Mental Status Exam (MMSE)
* Current unstable or untreated medical illness
* Drug or alcohol misuse- severe alcohol/cannabis disorder or any other substance use disorder except nicotine.
* Recurrent psychotropic medication change or initiation within the last 3 months
* Initiation of psychotherapy within the last 3 months
* Current or past Attention Deficit Hyperactivity Disorder (ADHD) diagnosis
* Chronic pain that may affect sitting down and still for approximately 30 minutes
* Current cognitive impairments as a result of a traumatic brain injury, as determined by a clinical evaluation
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Research Foundation for Mental Hygiene, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yuval Y Neria
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
# 7960
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.